Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02428660 · ClinicalTrials.gov registry record · NA
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
A NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related, sponsored by Genelex Corporation.
- Completed
- Registry status
- NA
- Development phase
- 341
- Enrollment target
- 1
- Study location
NCT02428660: Completed NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related, sponsored by Genelex Corporation.
NCT02428660 is a NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related that has completed, run by Genelex Corporation. The registered enrollment target is 341 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02428660, a NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related, has completed, sponsored by Genelex Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 341 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems. More specifically, cytochrome DNA testing, which provides information with regards to participant specific metabolism of medications, will be used in the evaluation of participant medication regimens. The overall aim of the project is to evaluate if the addition of genetic CYP testing to a standardized MTM Program provides increased clinical value. To answer this question, the investigators will look at the drug therapy problems (DTPs) identified by the genetic test compared to those DTPs discovered without the test.
Primary Outcome
Tabulation of the number of drug therapy problems identified by drug \& gene interaction risk analysis, with and without genetic testing.
Conditions Studied
Interventions
- OTHER MTM
- GENETIC Pharmacogenetic testing
- OTHER Software-based drug & gene interaction risk analysis
Study Locations (1)
Utah
- VRx Pharmacy Services - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-02 |
| Phase | NA |
What the finished NCT02428660 record still lists
NCT02428660 is an interventional study that assigns participants to a tested intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 9 conditions, with Drug Metabolism, Poor, CYP2D6-Related appearing as the primary indexed condition, and to 3 interventions - of which MTM is the first listed.
NCT02428660 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT02428660 about?
NCT02428660 is a clinical study titled "Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM". This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems. More specifically, cytochrome DNA testing, which provides information with regards to participant specific...
What is the current status of trial NCT02428660?
This trial is currently completed. It is a NA study. The enrollment target is 341 participants. The study started on 2015-02. Estimated completion is 2017-02.
What conditions does trial NCT02428660 study?
This clinical trial studies the following conditions: Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related, CYP2D6 Polymorphism, Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant.
What interventions are being tested in trial NCT02428660?
The interventions under investigation include: MTM (OTHER), Pharmacogenetic testing (GENETIC), Software-based drug & gene interaction risk analysis (OTHER).
Who is sponsoring clinical trial NCT02428660?
This trial is sponsored by Genelex Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02428660 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Metabolism, Poor, CYP2D6-Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02428660's enrollment target sits among peer trials
341 302nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia